Accurate Clinical Research Inc
Welcome,         Profile    Billing    Logout  
 21 Trials 
45 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kivitz, Alan
FORWARD OL, NCT04762498: A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout

Completed
4
50
US
Pegloticase, Methotrexate (MTX)
Amgen
Uncontrolled Gout, Chronic Gout
05/23
12/23
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Completed
4
191
US
Pegloticase with MTX, Methotrexate
Amgen
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
01/24
03/24
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Recruiting
4
240
US
Pegloticase, Methotrexate
Amgen
Gout
09/25
05/26
BE-EARLY, NCT06411249: A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)

Recruiting
4
350
Europe, Japan, US, RoW
Belimumab (GSK1550188), BEL (BENLYSTA)
GlaxoSmithKline
Systemic Lupus Erythematosus
04/27
05/29
COVER-CoAd, NCT05543642: The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients

Active, not recruiting
4
129
US
Hepatitis A vaccine, Havrix, Diphtheria, pertussis, and tetanus booster vaccine, Boostrix
Oregon Health and Science University
Rheumatic Diseases
01/25
12/25
RA-BRANCH, NCT04086745: A Study of Baricitinib in Participants With Rheumatoid Arthritis

Recruiting
4
1300
US
Baricitinib, LY3009104, TNF Inhibitor, Etanercept, Adalimumab
Eli Lilly and Company, Incyte Corporation
Rheumatoid Arthritis
12/24
02/26
NCT04638647 / 2020-004284-98: Secukinumab Open Label Roll-over Extension Protocol

Recruiting
4
715
Europe, US, RoW
Secukinumab s.c. injection
Novartis Pharmaceuticals
Autoimmunity, Inflammation
12/27
02/28
RESET-RA, NCT04539964: Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

Active, not recruiting
3
243
US
Implant Procedure, Surgical placement of vagus nerve stimulator inside the neck, Conventional Synthetic DMARD, Background therapy with conventional synthetic DMARD, Active stimulation, Non-active stimulation
SetPoint Medical Corporation
Rheumatoid Arthritis
05/24
10/27
NCT06269705: ZILRETTA in Subjects With Shoulder Osteoarthritis

Recruiting
3
250
US
ZILRETTA, TCA-IR, Placebo, Normal Saline
Pacira Pharmaceuticals, Inc
Glenohumeral Osteoarthritis
08/25
08/25
ORCA-OL, NCT06435221: Safety Study of Cytisinicline in Adult Combustible And/or E-cigarette Smokers

Active, not recruiting
3
650
US
Cytisinicline, Cytisine
Achieve Life Sciences
Smoking Cessation, Vaping Cessation
12/25
12/25
NAV3-33, NCT05246280: Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

Terminated
3
196
US
TC99m-tilmanocept, tilmanocept, Lymphoseek
Navidea Biopharmaceuticals
Rheumatoid Arthritis
07/24
07/24
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriatic Arthritis, Obesity
04/26
08/26
NCT05722522: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Active, not recruiting
3
34
Europe, Canada, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
GCAptAIN, NCT04930094: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Active, not recruiting
3
354
Europe, Canada, US, RoW
Secukinumab 300 mg, AIN457, Placebo, Placebo Comparator, Secukinumab 150 mg
Novartis Pharmaceuticals
Giant Cell Arteritis (GCA)
04/25
07/27
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
NEPTUNUS-1, NCT05350072 / 2020-005661-14: Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
276
Europe, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2100
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Knee Pain Chronic, Knee Osteoarthritis, Obstructive Sleep Apnea
04/26
05/26
RA-PROPR, NCT04692493: RA-PRO PRAGMATIC TRIAL

Recruiting
3
924
Canada, US
targeted synthetic DMARD class, non-TNFi-biologic class
University of Alabama at Birmingham, Patient-Centered Outcomes Research Institute
Rheumatoid Arthritis
02/27
12/28
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease

Active, not recruiting
3
9541
Europe, Canada, Japan, US, RoW
Obicetrapib, Placebo
NewAmsterdam Pharma, Monash University
Atherosclerotic Cardiovascular Disease
11/26
11/26
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Ianalumab (VAY736), Placebo
Novartis Pharmaceuticals
Sjogrens Syndrome
08/28
07/30
NCT05658575 / 2019-002717-19: Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare

Recruiting
2/3
300
Europe, US, RoW
Dapansutrile, OLT1177, Placebo Tablet
Olatec Therapeutics LLC, Olatec Therapeutics LLC
Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
09/25
10/25
OA05, NCT05620563: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 In Participants With Osteoarthritis Pain

Completed
2
147
US
LY3857210, Placebo
Eli Lilly and Company
Osteoarthritis
06/23
06/23
NCT05630196: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Chronic Low Back Pain

Completed
2
138
US
LY3857210, Placebo
Eli Lilly and Company
Chronic Low-back Pain
06/23
06/23
NCT05620576: A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05).

Completed
2
131
US
LY3857210, Placebo
Eli Lilly and Company
Diabetic Peripheral Neuropathic Pain
07/23
08/23
RESOLUTION-1, NCT05516758: A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

Active, not recruiting
2
491
Europe, Canada, Japan, US, RoW
Peresolimab, Placebo
Eli Lilly and Company
Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases
11/23
01/25
NCT06312020: A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjogren's Syndrome

Recruiting
2
262
Europe, US, RoW
HZN-1116, VIB1116, Placebo
Amgen
Sjogren's Syndrome
06/26
02/27
NCT06293365: Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Recruiting
2
140
Europe, Canada, US
VAY736 1ml PFS, Ianalumab, VAY736 2 ml PFS, VAY736 2ml AI
Novartis Pharmaceuticals
Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
07/25
02/29
CPMP, NCT05986292: A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

Recruiting
2
10000
US
LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo
Eli Lilly and Company
Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
04/27
04/27
NCT06130540: Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Recruiting
1
60
Europe, US, RoW
Secukinumab, AIN457
Novartis Pharmaceuticals
Giant Cell Arteritis, Polymyalgia Rheumatica
05/25
07/25
DONATELLO, NCT05835895: Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis

Active, not recruiting
1
67
US
GNSC-001, sc-rAAV2.5IL-1Ra, transient immune-modulation, Placebo
Genascence Corporation, California Institute for Regenerative Medicine (CIRM)
Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis
05/25
05/29
R-2487-RA01, NCT05961592: R-2487 in Patients with Rheumatoid Arthritis

Recruiting
1
36
US
R-2487, Drug
Rise Therapeutics LLC
Arthritis, Rheumatoid
11/25
01/26
NCT04862117: Long Term Extension of Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)

Active, not recruiting
N/A
14
US
SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System, SetPoint System
SetPoint Medical Corporation
Rheumatoid Arthritis
01/22
01/22
NCT03631225: The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis

Recruiting
N/A
1500
US
Vectra
Sequenom, Inc., Laboratory Corporation of America
Rheumatoid Arthritis (RA)
09/25
09/25
NCT05003310: ConsideRAte Study - Splenic Stimulation for RA

Recruiting
N/A
28
Europe, US
Active Stimulation, Sham Stimulation, Baricitinib, Background Treatment
Galvani Bioelectronics, NAMSA, Q2 Solutions
Rheumatoid Arthritis
07/27
04/32
Sulich, Andrew J
REPLENISH-EXT, NCT06331312: Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

Recruiting
3
300
Europe, Japan, US, RoW
Secukinumab
Novartis Pharmaceuticals
Polymyalgia Rheumatica
12/27
02/28
GCAptAIN, NCT04930094: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Active, not recruiting
3
354
Europe, Canada, US, RoW
Secukinumab 300 mg, AIN457, Placebo, Placebo Comparator, Secukinumab 150 mg
Novartis Pharmaceuticals
Giant Cell Arteritis (GCA)
04/25
07/27
REPLENISH, NCT05767034: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Active, not recruiting
3
381
Europe, Canada, Japan, US, RoW
Secukinumab 300 mg, AIN457, Secukinumab 150 mg, Placebo to secukinumab
Novartis Pharmaceuticals
Polymyalgia Rheumatica
09/25
02/26
NCT04186559: Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers

Not yet recruiting
2
60
US
Topical Pentoxifylline Gel (Vehicle +PTX), Trental, Topical Placebo Gel (Vehicle)
Silk Road Therapies, Inc.
Behcet Syndrome, Behcet Disease
11/24
12/24
Norton, Hillary
NCT04511702: Infusion Duration Study To Assess Tolerability of Pegloticase Administered With a Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate

Completed
4
191
US
Pegloticase with MTX, Methotrexate
Amgen
Chronic Uncontrolled Gout, Gout, Uncontrolled Gout
01/24
03/24
NCT06229145: A Trial to Investigate the Non-inferiority of Pegloticase Administered Every 4 Weeks (Q4W) With MTX Compared With Every 2 Weeks (Q2W) With MTX in Participants With Uncontrolled Refractory Gout

Recruiting
4
240
US
Pegloticase, Methotrexate
Amgen
Gout
09/25
05/26
TOGETHER-PsA, NCT06588296: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriatic Arthritis, Obesity
04/26
08/26
NCT05722522: Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy

Active, not recruiting
3
34
Europe, Canada, US, RoW
Secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Rotator Cuff Tendinopathy
10/24
12/24
REPLENISH, NCT05767034: Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)

Active, not recruiting
3
381
Europe, Canada, Japan, US, RoW
Secukinumab 300 mg, AIN457, Secukinumab 150 mg, Placebo to secukinumab
Novartis Pharmaceuticals
Polymyalgia Rheumatica
09/25
02/26
RA-PROPR, NCT04692493: RA-PRO PRAGMATIC TRIAL

Recruiting
3
924
Canada, US
targeted synthetic DMARD class, non-TNFi-biologic class
University of Alabama at Birmingham, Patient-Centered Outcomes Research Institute
Rheumatoid Arthritis
02/27
12/28
NCT06130540: Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Recruiting
1
60
Europe, US, RoW
Secukinumab, AIN457
Novartis Pharmaceuticals
Giant Cell Arteritis, Polymyalgia Rheumatica
05/25
07/25

Download Options